Stay updated on JCAR014 and Durvalumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.

Latest updates to the JCAR014 and Durvalumab in Lymphoma Clinical Trial page
- Check5 days agoChange DetectedSite revision v3.4.2 was added and the government funding status notice from v3.4.1 was removed; no study content changes were made. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check12 days agoChange DetectedA government funding lapse notice banner was added and the site was updated to revision 3.4.1, replacing 3.4.0.SummaryDifference0.2%

- Check19 days agoChange DetectedAdded a Show glossary option and new metadata items: Last Update Submitted that Met QC Criteria and No FEAR Act Data, plus a revision note indicating Revision: v3.4.0. Removed the corresponding older items Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded a Washington Locations section and updated the page revision from v3.3.2 to v3.3.3; removed HHS Vulnerability Disclosure and Washington Locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page shows a new revision: v3.3.2, and the previous revision v3.3.1 is removed; no study details appear to be modified.SummaryDifference0.0%

- Check84 days agoChange DetectedUpdated the Publications section description to indicate that publications are automatically filled from PubMed, a public database, and may not be about the study. Revision label updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

Stay in the know with updates to JCAR014 and Durvalumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.